Research programme: pain therapeutics - NAEJA
Latest Information Update: 29 Feb 2008
At a glance
- Originator NAEJA Pharmaceutical
- Developer AstraZeneca; NAEJA Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 29 Feb 2008 Preclinical development is ongoing